多种源自植物的天然生物活性化合物已证明在治疗癌症、慢性病和炎症等各种疾病方面具有重要的临床意义。越来越多的研究表明植物源性囊泡样纳米颗粒 (PDVLN) 作为药物输送系统 (DDS) 的有力候选者的潜力。 PDVLN 的生产具有成本效益、无毒、无免疫原性以及令人着迷的生物相容性。在这篇综述中，我们试图全面回顾并巩固 PDVLN 作为下一代药物递送纳米平台的地位。我们的目的是让读者快速了解 PDVLN 的最新进展，包括其生物发生、特征、组成、给药途径、优势和应用。此外，我们还讨论了 PDVLN 的优点和局限性。我们预计 PDVLN 在药物递送中的作用将显着增强，从而在可预见的未来将其定位为下一代治疗方式。

A wide variety of natural bioactive compounds derived from plants have demonstrated significant clinical relevance in the treatment of various diseases such as cancer, chronic disease, and inflammation. An increasing number of studies have surfaced that give credence to the potential of plant-derived vesicle-like nanoparticles (PDVLNs) as compelling candidates for a drug delivery system (DDS). PDVLNs are cost-effective production, non-toxicity and non-immunogenicity and fascinating bi-ocompatibility. In this review, we attempt to comprehensively review and consolidate the position of PDVLNs as next-generation drug delivery nanoplatforms. We aim to give a quick glance to readers of the current developments of PDVLNs, including their biogenesis, characteristic features, composition, administration routes, advantages, and application. Further, we discuss the advantages and limitations of PDVLNs. We expect that the role of PDVLNs in drug delivery will be significantly enhanced, thus positioning them as the next generation of therapeutic modalities in the foreseeable future.